Ulcerative colitis

This study looks at the long-term safety of brazikumab, a drug given as a shot every 4 weeks, for people with moderate to severe ulcerative colitis. Participants had already taken part in an earlier study of brazikumab. The goal is to see if the drug remains safe over a longer pe…

This early-phase study tested an injectable drug called NP-201 acetate in healthy volunteers and people with mild-to-moderate ulcerative colitis. The goal was to check safety, how the body processes the drug, and early signs of effectiveness. The trial was terminated early, so on…

This phase 2 trial tested brazikumab in 242 adults with moderate-to-severe ulcerative colitis. Participants received either brazikumab or a placebo intravenously and then as injections over 54 weeks. The goal was to see if the drug could improve symptoms and heal the colon lining…

This study looks at people with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are in deep remission. It compares two methods for gradually increasing the time between infliximab infusions: one based on symptoms and one based on drug levels in the blood. T…

This study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the da…

This study tested an experimental daily tablet called VTX002 in people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 213 participants were randomly assigned to receive one of two doses of VTX002 or a placebo for 13 weeks, with the option …

This early-stage study tested whether injecting donor stem cells (remestemcel-L) into the colon could help people with severe ulcerative colitis that hadn't responded to other treatments. Only 7 adults took part before the trial was stopped early. The main goal was to check safet…

This study tested whether a bile acid supplement called UDCA could reduce inflammation and improve quality of life in people with pouchitis, a complication after ulcerative colitis surgery. Only 2 participants were enrolled before the study was terminated. The goal was to see if …

This study tested a drug called vixarelimab in 79 people with moderate to severe ulcerative colitis (UC) who had not responded well to other treatments. The goal was to see if the drug could help control the disease and reduce symptoms like diarrhea and bleeding. The study was st…

This study tested an experimental oral drug, PF-07054894, in adults aged 18-75 with mild to severe ulcerative colitis (UC). The goal was to see if the drug could safely help control the disease and reduce symptoms like diarrhea and rectal bleeding. The trial was terminated early,…

This study looked at the safety and effectiveness of the drug ozanimod for people with moderate to severe ulcerative colitis. It aimed to see if the drug could improve symptoms like diarrhea and rectal bleeding, and how it affected quality of life. The study was terminated early,…

This early-stage trial tested a new antibody drug (BB-TL1A-VIAL-HLE) in 16 healthy volunteers and people with moderate-to-severe ulcerative colitis. The goal was to check safety and see if it could improve colon inflammation. However, the study was terminated early, so we have li…

This study tested a new drug called efavaleukin alfa in 221 adults with moderate to severe ulcerative colitis. The goal was to see if it could help patients achieve remission after 12 weeks of treatment. The trial was terminated early, so final results are limited, but the data m…

This phase 3 trial compared AVT16, a proposed biosimilar, to the approved drug Entyvio (vedolizumab) in 301 adults with moderate to severe ulcerative colitis. Participants received IV infusions over nearly a year. The study aimed to see if AVT16 works as well and is as safe as En…

This study looked at how well the drug tofacitinib (Xeljanz) works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. It measured symptom improvement and gut inflammation using stool samples. The study was small with 18 participants…

This study tested an experimental oral treatment called VE202 for people with mild-to-moderate ulcerative colitis, a chronic inflammatory bowel disease. The treatment uses live bacteria to help restore gut balance. The trial was terminated early, so results are limited. Participa…

This study tested a drug called bertilimumab in 32 adults with moderate to severe ulcerative colitis. The goal was to see if it could reduce disease activity compared to a placebo. The trial was terminated early, so results are limited and no clear benefit was established.

This study tested whether statins, a common cholesterol drug, could change the gut bacteria in people with ulcerative colitis or Crohn's disease to a healthier type. The goal was to see if this change could reduce disease activity. The study was terminated early, so results are l…

This study tested a drug called efavaleukin alfa in people with moderate to severe ulcerative colitis who had already completed a previous study. The goal was to see if the drug is safe and works over a longer period, up to 104 weeks. The study was terminated early and enrolled o…

This pilot study tested whether placing a special mesh during ileostomy closure surgery could prevent hernias in people with inflammatory bowel disease. Only 8 patients were enrolled before the study was stopped. The main goal was to check safety, like infections or wound problem…

This study looked at whether adding high-dose steroid pulses to the usual oral steroid course could help people with moderate ulcerative colitis flares achieve remission without needing other treatments. The trial was terminated early and enrolled 75 adults with left-sided or ext…

This study aimed to see if certain substances in stool and blood can predict whether the gut lining has healed in people with moderate to severe ulcerative colitis. Researchers planned to measure these markers in 62 adults before and after treatment. The study was terminated earl…